Lentiviral vectors pseudotyped with baculovirus gp64 efficiently transduce mouse cells in vivo and show tropism restriction against hematopoietic cell types in vitro
- 22 January 2004
- journal article
- research article
- Published by Springer Nature in Gene Therapy
- Vol. 11 (3) , 266-275
- https://doi.org/10.1038/sj.gt.3302170
Abstract
The envelope glycoprotein from vesicular stomatitis virus (VSV-G) has been used extensively to pseudotype lentiviral vectors, but has several drawbacks including cytotoxicity, potential for priming of immune responses against transgene products through efficient transduction of antigen-presenting cells (APCs) and sensitivity to inactivation by human complement. As an alternative to VSV-G, we extensively characterized lentiviral vectors pseudotyped with the gp64 envelope glycoprotein from baculovirus both in vitro and in vivo. We demonstrated for the first time that gp64-pseudotyped vectors could be delivered efficiently in vivo in mice via portal vein injection. Following delivery, the efficiency of mouse cell transduction and the transgene expression is comparable to VSV-G-pseudotyped vectors. In addition, we found that gp64-pseudotyped lentiviral vectors could efficiently transduce a variety of cell lines in vitro, although gp64 showed a more restricted tropism than VSV-G, with especially poor ability to transduce hematopoietic cell types including dendritic cells (DCs). Although we found that gp64-pseudotyped vectors are also sensitive to inactivation by human complement, gp64 nevertheless has advantages over VSV-G, because of its lack of cytotoxicity and narrower tropism. Consequently, gp64 is an attractive alternative to VSV-G because it can efficiently transduce cells in vivo and may reduce immune responses against the transgene product or viral vector by avoiding transduction of APCs such as DCs.Keywords
This publication has 50 references indexed in Scilit:
- Large-Scale Production of Pseudotyped Lentiviral Vectors Using Baculovirus GP64Human Gene Therapy, 2003
- Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivoBlood, 2002
- Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primatesBlood, 2002
- lacZTransgenic Rats Tolerant forβ-Galactosidase: Recipients for Gene Transfer Studies UsinglacZas a Reporter GeneHuman Gene Therapy, 2002
- Efficient Gene Delivery and Targeted Expression to HepatocytesIn Vivoby Improved Lentiviral VectorsHuman Gene Therapy, 2002
- Production of human clotting Factor IX without toxicity in mice after vascular delivery of a lentiviral vectorNature Biotechnology, 2002
- Lentiviral Vector-Mediated Tyrosinase-Related Protein 2 Gene Transfer to Dendritic Cells for the Therapy of MelanomaHuman Gene Therapy, 2001
- A New-Generation Stable Inducible Packaging Cell Line for Lentiviral VectorsHuman Gene Therapy, 2001
- Efficient Gene Transfer to Human Peripheral Blood Monocyte-Derived Dendritic Cells Using Human Immunodeficiency Virus Type 1-Based Lentiviral VectorsHuman Gene Therapy, 2000
- VSV-G Pseudotyped Lentiviral Vector Particles Produced in Human Cells Are Inactivated by Human SerumMolecular Therapy, 2000